TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Caribou Biosciences
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Caribou Biosciences reported promising first clinical data for CB-011, an off-the-shelf allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma, with 92% overall response rate and a manageable safety profile.

Insights
BACpO   positive

First Investor Day in 14 years, recent earnings beat, and potential for optimistic outlook on consumer banking and economic trends


CRBU   positive

Reported strong initial clinical trial results with high response rates, no serious adverse events, and potential for a breakthrough therapy in multiple myeloma treatment